PPARγ activation in adipocytes is sufficient for systemic insulin sensitization
Shigeki Sugii, Peter Olson, Dorothy D. Sears, Maziyar Saberi, Annette R. Atkins, Grant D. Barish, Suk-Hyun Hong, Glenda L. Castro, Yun-Qiang Yin, Michael C. Nelson, Gene Hsiao, David R. Greaves, Michael Downes, Ruth T. Yu, Jerrold M. Olefsky, Ronald M. Evans;Shigeki Sugii;Peter Olson;Dorothy D. Sears;Maziyar Saberi;Annette R. Atkins;Grant D. Barish;Suk-Hyun Hong;Glenda L. Castro;Yun-Qiang Yin;Michael C. Nelson;Gene Hsiao;David R. Greaves;Michael Downes;Ruth T. Yu;Jerrold M. Olefsky;Ronald M. Evans;
Proceedings of the National Academy of Sciences of the United States of America2009Vol. 106pp. 22504-
163
evans2009proceedingspparγ
Abstract
Although peroxisome proliferator-activated receptor gamma (PPARγ) agonists such as thiazolidinediones (TZDs) are widely used to treat type 2 diabetes, how its activation in individual tissues contributes to TZD's therapeutic action remains controversial. ...